There are currently 178 active clinical trials seeking participants for Multiple Myeloma research studies. The states with the highest number of trials for Multiple Myeloma participants are California, New York, Ohio and Texas.
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
NCT04879043
Recruiting
This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2024
Locations: Winship Cancer Institute of Emory University, Atlanta, Georgia +15 locations
Conditions: Multiple Myeloma, Plasma Cell Disorder
Register for Updates
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
NCT05767359
Recruiting
The goal of this research study is to test if ciltacabtagene autoleucel (cilta-cel) is safe and effective in treating participants with high-risk, smoldering myeloma. The names of the treatment interventions used in this study are: * Cilta-cel (or chimeric antigen receptor T cells) * Cyclophosphamide (a lymphodepleting chemotherapy) * Fludarabine (a lymphodepleting chemotherapy)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Multiple Myeloma, Smoldering Multiple Myeloma
Register for Updates
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
NCT04731844
Recruiting
To explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a day in early stage prostate cancer patient undergoing active surveillance or patients on observation for MGUS/ low-risk smoldering myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2024
Locations: University of Rochester, Rochester, New York
Conditions: Prostate Cancer, Multiple Myeloma, Smoldering Multiple Myeloma (SMM), Monoclonal Gammopathy of Undetermined Significance
Register for Updates
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
NCT06483139
Recruiting
Objective 1: To test whether treatment with plasma exchange improves renal recovery in patients with light chain cast nephropathy Objective 2: To compare renal outcomes among patients treated with plasma exchange versus daratumumab-based regimens versus non-daratumumab based-regimens.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Multiple Myeloma, Light Chain Nephropathy, Acute Kidney Injury
Register for Updates
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
NCT05646576
Recruiting
The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT). After completion of an open pilot, participants will be randomly assigned into one of two study intervention groups. The names of the study intervention groups involved in this study are: * Palliative care (PEACE) plus usual oncology care * Usual care (standar... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Hematologic Malignancy, Blood Cancer, Lymphoma, Leukemia, Multiple Myeloma
Register for Updates
Biomarker for Infection Risk in CLL and MM
NCT05844033
Recruiting
The aim of this research study is to use advanced immunology laboratory analysis to identify a more precise blood test that will predict infection risk in patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) or Multiple Myeloma (MM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Multiple Myeloma, Chronic Lymphocytic Leukemia
Register for Updates
Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
NCT06149910
Recruiting
All4Cure is partnering with community oncology practices participating in the Quality Cancer Care Alliance (QCCA) and Exigent Research to develop a clinical pathway that standardizes the evaluation, treatment and ongoing management of patients with newly diagnosed multiple myeloma who wish to achieve and maintain MRD negativity. This is a longitudinal retrospective study that will collect data from three separate cohorts of patients with newly diagnosed multiple myeloma (NDMM). The cohorts clas... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: All4Cure, Seattle, Washington
Conditions: Multiple Myeloma, Multiple Myeloma Without Mention of Remission
Register for Updates
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06399393
Recruiting
The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +117 locations
Conditions: Multiple Myeloma
Register for Updates
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
NCT04771572
Recruiting
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.
Gender:
ALL
Ages:
13 years and above
Trial Updated:
04/23/2024
Locations: University of Chicago, Chicago, Illinois +7 locations
Conditions: Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myeodysplastic Syndrome, Myelofibrosis, Myelodysplastic/Myeloproliferative Neoplasm, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Neoplasm in Blast Phase
Register for Updates
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
NCT04176718
Recruiting
This research study is studying the combination of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma. Relapsed and Refractory Multiple Myeloma is the condition of returned or previous treatment resistant Multiple Myeloma. This research study involves two study drugs and two standard of care drugs. * The names of the study drugs involved in this study are: * Carfilzomib * Daratumumab * The names of the standard of c... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/14/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Relapse
Register for Updates
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT03091257
Recruiting
This research study is studying a targeted therapy as a possible treatment for multiple myeloma. The names of the study drugs involved in this study are: * Trametinib * Dabrafenib
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Multiple Myeloma
Register for Updates
Elranatamab in R/R Multiple Myeloma
NCT06138275
Recruiting
This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma
Register for Updates